INCB040093 structure
|
Common Name | INCB040093 | ||
---|---|---|---|---|
CAS Number | 1262440-25-4 | Molecular Weight | 421.451 | |
Density | 1.6±0.1 g/cm3 | Boiling Point | N/A | |
Molecular Formula | C20H16FN7OS | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of INCB040093A novel potent, selective, orally available PI3Kδ inhibitor with IC50 of 31 nM; displays 74 to >900-fold selectivity for the other PI3K family members, and does not inhibit a panel of 57 additional kinases; potently inhibits cellular proliferation CD19+ human or CD21+ canine primary B cells with IC50 of 1-3 nM, reduces anti-FcR-induced basophil activation in the presence of human whole blood (IC50=33 nM); demonstrates promising efficacy in patients with Hodgkin's lymphoma in clinical studies. Blood Cancer Phase 2 Clinical |
Name | Dezapelisib |
---|---|
Synonym | More Synonyms |
Description | A novel potent, selective, orally available PI3Kδ inhibitor with IC50 of 31 nM; displays 74 to >900-fold selectivity for the other PI3K family members, and does not inhibit a panel of 57 additional kinases; potently inhibits cellular proliferation CD19+ human or CD21+ canine primary B cells with IC50 of 1-3 nM, reduces anti-FcR-induced basophil activation in the presence of human whole blood (IC50=33 nM); demonstrates promising efficacy in patients with Hodgkin's lymphoma in clinical studies. Blood Cancer Phase 2 Clinical |
---|---|
References | References 1. Shin N, et al. J Pharmacol Exp Ther. 2017 Nov 10. pii: jpet.117.244947. View Related Products by Target PI3K Blood Cancer |
Density | 1.6±0.1 g/cm3 |
---|---|
Molecular Formula | C20H16FN7OS |
Molecular Weight | 421.451 |
Exact Mass | 421.112091 |
LogP | 2.57 |
Index of Refraction | 1.797 |
INCB040093 |
2K59L7G59M |
5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-(3-fluorophenyl)-3-methyl-7-[(1S)-1-(9H-purin-6-ylamino)ethyl]- |
6-(3-Fluorophenyl)-3-methyl-7-[(1S)-1-(3H-purin-6-ylamino)ethyl]-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one |
UNII:2K59L7G59M |
Dezapelisib |